Disease Modifying Therapies

The following is a list of disease modifying therapies for Multiple Sclerosis as of 7/9/2023

MONOCLONAL ANTIBODIES

• Natalizumab (Tysabri)
• Ocrelizumab (Ocrevus) 10-year Study Results
• Rituximab (Rituxan)
• Ofatumumab (Arzerra)
• Ublituximab (Kesimpta)
• Alemtuzumab (Lemtrada)
• Forlamaub (Secondary Progressive MS) 1-year Study Results

ORAL THERAPIES

• Fumarates
  • Dimethyl fumarate (Tecfidera)
• Teriflunomide (Aubagio)
• S1PR modulators
  • (fingolimod
  • siponimod
  • ozanimod
  • ponesimod
• Cladribine (Mavenclad)

PLATFORM INJECTION THERAPIES

• Interferons (Avonex, Betaferon, Extavia, Plegridy, Rebif)
• Glatiramer acetate (Copaxone)

OTHER TREATMENTS

• Azathioprine (Imuran)
• Cyclophosphamide (chemotherapy, B-cell depletion therapy)
• Glucocorticoids (steroids: prednisone, methylprednisolone, and dexamethasone)
• Intravenous immune globulin
• Laquinimod (Nerventra - discontinued)
• Mitoxantrone (Novantrone)
• Stem cell transplantation (HSCT)